To ask the Secretary of State for Health what assessment he has made of the value for money for the NHS in the treatment of primary hypercholesterolaemia by use of cholesterol absorption inhibitors. (181465)

In November 2007, the National Institute for Health and Clinical Excellence (NICE) published its guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia to the National Health Service. NICE recommended the use of ezetimibe having carried out a thorough review of the clinical and economic evidence. We have made no separate assessment.